Oncobiologics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Oncobiologics and buy or sell other stocks, ETFs, and their options commission-free!About ONS
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.
CEOLawrence A. Kenyon, CPA
CEOLawrence A. Kenyon, CPA
Employees—
Employees—
HeadquartersIselin, New Jersey
HeadquartersIselin, New Jersey
Founded2010
Founded2010
Employees—
Employees—
ONS Key Statistics
Market cap92.84M
Market cap92.84M
Price-Earnings ratio-1.91
Price-Earnings ratio-1.91
Dividend yield—
Dividend yield—
Average volume2.13M
Average volume2.13M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$3.39
52 Week high$3.39
52 Week low$0.79
52 Week low$0.79
Stock Snapshot
The current Oncobiologics(ONS) stock price is $0.79, with a market capitalization of 92.84M. The stock trades at a price-to-earnings (P/E) ratio of -1.91.
On 2025-12-11, Oncobiologics(ONS) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 2.13M.
The stock's 52-week range extends from a low of $0.79 to a high of $3.39.
The stock's 52-week range extends from a low of $0.79 to a high of $3.39.